The tweet was deleted by the author.
But we saved everything 🙂.
Kura Oncology has announced the launch of Caspian Therapeutics, a new separately financed company focused on the development of small-molecule menin inhibitors for diabetes and cardiometabolic diseases.
Drawing on Kura Oncology's expertise in scientific research and drug development related to menin inhibition, the Caspian Therapeutics team plans to drive forward new therapeutic options in the field. The move signals a strategic diversification for Kura Oncology into metabolic disease applications.
View post on X Loading...
Kura Oncology has previously emphasized its commitment to patient-centered care and collaboration under the leadership of COO Kathy Ford, as detailed in a recent overview of company culture (/news/companies/show/3134835-kura-oncology-patient-culture/). The company has also engaged with the investment community by attending major conferences hosted by Wells Fargo and Cantor Fitzgerald (/news/companies/show/3211804-kura-oncology-investor-conferences/). These activities highlight Kura Oncology’s active role in both operational strategy and investor relations.